MicroRNA-Based Test Identifies Squamous Lung Cancer With 96% Sensitivity
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




MicroRNA-Based Test Identifies Squamous Lung Cancer With 96% Sensitivity

NEW YORK -- March 10, 2009 -- A microRNA-based diagnostic test can objectively identify squamous lung cancer with 96% sensitivity, according to a study released early online and appearing in an upcoming print issue of the Journal of Clinical Oncology.

Recent advances in treatment of lung cancer require greater accuracy in the subclassification of non-small-cell lung cancer (NSCLC). Targeted therapies that inhibit tumour angiogenesis pose higher risk for adverse response in cases of squamous cell carcinoma, according to background information from the article.

Harvey Pass, MD, New York University (NYU) Cancer Institute at NYU Langone Medical Center, New York, New York, and colleagues used high-throughput microarray to measure microRNA expression levels in 252 patients with lung cancer.

The researchers identified hsa-miR-205 as a highly specific marker for squamous cell lung carcinoma. A microRNA-based qRT-PCR assay that measures expression of hsa-miR-205 reached sensitivity of 96% and specificity of 90% in the identification of squamous cell lung carcinomas from NSCLC.

"The results of this study are very encouraging," said Dr. Pass. "The study has demonstrated that a microRNA biomarker successfully identifies squamous lung cancer with high reproducibility, sensitivity, and specificity."

"The study certainly demonstrates the power of microRNAs in correctly classifying lung cancer and hopefully can immediately translate into more accurate choices of targeted therapies as well as cytotoxics for the disease."

SOURCE: New York University Langone Medical Center

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities